2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Plasma Cell Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4747 Penetration characteristics of ruxolitinib across blood-brain barrier in hemophagocytic lymphohistiocytosis: Dose response and azole-mediated drug interaction

Kai Qing, Jie Fang2, Xiaohua Chen3, Yuqing He4, Jun Zhu5, Bo Lv6, Yuting Tao7, Fengxuan Zhang8, Wu Shishuang, MD9, Kai Xue, MD10
1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Zhujiang Hospital, Southern Medical University, Guangzhou, China
4 Department of Pharmacy, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090, China, Shanghai, China
5 Shanghai Liquan Hospital, Shanghai, China
6 Shanghai Liquan Hospital, Shanghai, China
7 Shanghai Liquan Hospital, Shanghai, China
8 The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China
9 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Introduction

CNS-HLH leads to poor clinical outcomes, and conventional intrathecal chemotherapy fails to control neuroinflammation effectively. Ruxolitinib, a selective JAK1/2 inhibitor, exerts therapeutic effects in HLH. We have demonstrated that ruxolitinib is capable of penetrating the blood-brain barrier (BBB) (Ji et al. J Cell Mol Med. 2026). However, clinical implications of this BBB permeability remain unclear. Specifically, the dose-exposure correlation and the impact of azole antifungal-mediated drug-drug interaction (DDI) on central drug levels have not been quantitatively clarified in HLH patients. This study aimed to characterize the BBB penetration profile of ruxolitinib at two fixed oral doses (10 mg twice daily and 15 mg twice daily), and quantify the effects of dose adjustment and concomitant azoles alter plasma and CSF trough concentrations and BBB penetration ratio, so as to provide pharmacokinetic (PK) evidence supporting individualized treatment for CNS-HLH. 

Methods

This single-center retrospective PK analysis recruited a total of 25 HLH patients maintained on fixed-dose ruxolitinib therapy at the Hematology Center of Ruijin Hospital, between January 2025 and July 2026. All participants fulfilled standardized HLH diagnostic criteria, reached PK steady state after continuous ruxolitinib administration for ≥5 drug half-lives, and underwent simultaneous peripheral blood collection and lumbar puncture to obtain paired plasma and cerebrospinal fluid (CSF) specimens. Exclusion criteria included severe decompensated hepatic/renal dysfunction, ruxolitinib interruption within 7 days before sampling, and incomplete matched plasma-CSF samples.

Ruxolitinib concentrations in plasma and CSF were measured via liquid chromatography-tandem mass spectrometry (LC-MS/MS) and presented as median (interquartile range, IQR). The BBB penetration ratio was defined as the CSF-to-plasma trough concentration ratio, expressed as a percentage. Patients were divided into two dose subgroups (15 mg twice daily, n=13; 10 mg twice daily, n=12) and two medication subgroups (concomitant azole antifungals, n=5; no azoles, n=20). Exact Mann-Whitney U test (two-sided, α=0.05) was conducted for between-group comparisons.

 

Results

PK analysis revealed that ruxolitinib steadily penetrated the BBB of HLH patients, with a median overall penetration ratio of 11.64% [IQR 9.76, 18.08]. The median plasma trough concentration was 68.49 [39.85, 87.85] ng/mL in the 15 mg group versus 32.26 [19.87, 41.71] ng/mL in the 10 mg group (p=0.019), and median CSF trough concentration was 9.59 [4.27, 10.92] ng/mL versus 4.42 [2.81, 6.97] ng/mL (p=0.040). No significant intergroup difference was observed in BBB penetration ratio: 11.64% [9.04, 17.49] for 15 mg and 12.38% [10.07, 18.50] for 10 mg (p=0.650). For patients with or without concomitant azole antifungals: median plasma trough concentration was 54.31 [19.97, 81.77] ng/mL vs 40.62 [30.32, 72.30] ng/mL (p=0.974), median CSF trough concentration was 9.82 [6.96, 9.91] ng/mL vs 5.15 [3.85, 8.54] ng/mL (p=0.272), and BBB penetration ratio was 18.08% [12.12, 20.08] vs 11.28% [8.65, 16.25] (p=0.083). No statistically significant differences in plasma and CSF trough concentrations were found between the two groups, whereas a trend toward higher penetration ratio was observed in patients receiving azole antifungals. All 5 patients with CNS involvement had relief from neurological symptoms assessed by clinicians. 

Conclusion

This retrospective study confirmed that ruxolitinib can effectively cross the blood-brain barrier in patients with HLH. Dose escalation to 15 mg twice daily elevates systemic and central drug exposure significantly without altering the BBB penetration ratio, providing quantitative PK rationale for dose optimization. Concomitant azole antifungals yields a numerical upward trend in CSF-to-plasma penetration ratio, reminding clinicians to monitor this DDI for personalized dose adjustment. These PK findings establish a critical reference framework for precise ruxolitinib treatment of CNS-HLH. Furthermore, ruxolitinib demonstrated clinical efficacy in both dose groups, with symptomatic relief observed in all evaluated CNS-HLH patients, supporting its role as a viable systemic alternative when intrathecal access is impractical. Given the higher central exposure at 15 mg twice daily, prospective studies are warranted to further explore the optimal clinical application dose of ruxolitinib for CNS-HLH.

Kai Qing: No relevant conflicts of interest to declare.